References
- Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008; 358(10): 1037-1052.
- Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematol Am Soc Hematol Educ Program. 2005:1-12.
- Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85(6): 1504-1508.
- Zöller B, García de Frutos P, Hillarp A, Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica. 1999; 84(1):59-70.
- Djordjevic V, Rakicevic L, Gagic M, Nikolic A, Savic A. Simultaneous detection of factor V Leiden and factor II G20210A variants by a multiplex PCR on whole blood. Balkan J Med Genet. 2001; 4(1&2): 15-17.
- Djordjevic V, Stankovic M, Nikolic A, Antonijevic N, Rakicevic LJ, Divac A, Radojkovic M. PCR amplification on whole blood samples treated with different commonly used anticoagulants. Pediatr Hematol Oncol. 2006; 23(6): 517-521.
- Koebe J, Kirchhof P. Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. Europace. 2008; 10(4): 433-437.
- Papagiannis J, Papadopoulou K, Rammos S, Demosthenes Katritsis D. Cryoablation versus radiofrequency ablation for atrioventricular nodal reentrant tachycardia in children: long-term results. Hellenic J Cardiol. 2010; 51(2): 122-126.
- Lin JL, Stephen Huang SK, Lai LP, Ko WC, Tseng YZ, Lien WP. Clinical and electrophysiologic characteristics and long-term efficacy of slow-pathway catheter ablation in patients with spontaneous supraventricular tachycardia and dual atrioventricular node pathways without inducible tachycardia. J Am Coll Cardiol. 1998; 31(4): 855-860.
- O'Hara GE, Philippon F, Champagne J, Blier L, Molin F, Côté JM, Nault I, Sarrazin JF, Gilbert M. Catheter ablation for cardiac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec Heart Institute, Laval Hospital. Can J Cardiol. 2007; 23(Suppl B): 67B-70B. (Erratum: Can J Cardiol. 2009; 25(3): 140.)
- Mansourati J, Deharo JC, Graux P, Chappuis L, Durieu C, Dutoit A, Guillo P, Djiane P, Blanc JJ. Short and medium-term outcome after radiofrequency ablation of the atrioventricular junction. Arch Mal Coeur Vaiss. 1997; 90(7): 945-951. [Article in French]
- Darpö B, Walfridsson H, Aunes M, Bergfeldt L, Edvardsson N, Linde C, Lurje L, van der Linden M, Rosenqvist M. Incidence of sudden death after radiofrequency ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol. 1997; 80(9): 1174-1177.
- Haman L, Parízek P, Alý R, Duda J, Malý J. Analysis of thrombotic complications after catheter ablation. Acta Medica (Hradec Kralove). 2006; 49(1): 47-50.
- Aznar J, Vaya A, Estelles A, Mira Y, Segui R, Villa P, Ferrando F, Falco C, Corella D, Espana F. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000; 85(12): 1271-1276.
- Coen D, Zadro R, Honovic L, Banfic L, Stavljenic Rukavina A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001; 42(4): 488-492.
- Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342(8886-8887): 1503-1506.
- Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999; 19(3): 511-518.
- Mandala M, Curigliano G, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004; 15(4): 590-593.
- Almawi WY, Tamim H, Kreidy R, Timson G, Rahal E, Nabulsi M, Finan RR, Irani-Hakime N. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005; 19(3): 189-196.
- Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997; 78(6): 1426-1429.
- Howard TE, Marusa M, Boisza J, Young A, Sequeira J, Channell C, Guy C, Benson E, Duncan A. The prothrombin gene 3'-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood. 1998; 91(3):1092-1093.
- Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997; 17(9): 1662-1666.
- Nagorni-Obradovic Lj, Miljic P, Djordjevic V, Pesut D, Jovanovic D, Stojsic J, Stevic R, Radojkovic D. The prothrombin factor II G20210A mutation with pulmonary thromboembolism and a normal level of fibrin degradating products. Balkan J Med Genet. 2009; 12(2): 69-76.
- Yamamoto T, Ito M, Nagata S, Suzuki H, Tagawa A, Nagase M, Hishida AJ. Catastrophic exacerbation of antiphospholipid syndrome after lung adenocarcinoma biopsy. J Rheumatol. 2000; 27(8): 2035-2037.